Vertex's Price Pop by the Numbers: Does It Fly?

Shares of Vertex Pharmaceuticals rise 40% on positive test results

Jun 24, 2014 at 7:00PM
Longview

U.S. stocks finished lower on Tuesday, with the benchmark S&P 500 closing down 0.6%, while the narrower Dow Jones Industrial Average (DJINDICES:^DJI) lost 0.7%. The technology-heavy Nasdaq Composite Index (NASDAQINDEX:^IXIC) fell 0.1%. One Nasdaq component had a banner day, however, as shares of Vertex Pharmaceuticals (NASDAQ:VRTX) exploded higher, hitting a new 52-week high and closing up 40.4%, as the company announced that it will seek regulatory approval for an experimental cystic fibrosis drug later this year.

Vertexpharma Logo

Source: Wikipedia.

Vertex Phamaceuticals' annoucement follows positive results in two studies that looked at the efficacy of Vertex's experimental drug lumacaftor in combination with its currently approved therapy ivacaftor (brand name: Kalydeco), in cystic-fibrosis patients with two copies of a rare genetic mutation.

Cystic fibrosis is a rare disease to begin with, but add to that this genetic mutation, and Vertex estimates that the target market for the combination therapy is just 22,000 across North America, Europe and Australia. (While there is no single definition of a rare disease, in the U.S., the Rare Diseases Act of 2002 as "any disease or condition that affects less than 200,000 people in the United States" – a rate of approximately 1 in 1,500.)

Nevertheless, while the target market is very narrow, the price of treatment is very high. In this case, analysts are forecasting a cost of roughly $150,000 per annum. As such, Citigroup analyst Yaron Werber expects peak sales of $3.1 billion in 2015.

Now consider that the market added some $6.4 billion to Vertex's market capitalization today. If this combination therapy had been kept entirely secret until today, instead of being highly anticipated, and its approval were now a certainty, today's increase in market value would amount to "paying" roughly two times forward revenue for the new therapy – an absolute bargain! (That $6.4 billion is approximately two times Citigroup's 2015 sales estimate of $3.1 billion.)

But not so fast. Werber wrote today that the new results only increase "the likelihood for approval from 65% to 80%" but concedes "that it might be conservative." Using those figures, the increase in Vertex's market value is now equivalent to paying nearly 14 times forward revenue (or 6.4/ (3.1*0.15)), which starts to look a bit pricey, even compared with the often optimistic valuations prevalent across the biotechnology sector. Note that as of yesterday's close, Vertex itself was trading at 11.2 times the consensus revenue estimate for 2015.

On the other hand, if we assume instead that the odds of regulatory approval just went from two-thirds to certainty, the revenue multiple is above 6 -- a relative bargain.

Bottom line: If you believe that Vertex was fairly valued yesterday, then today's jump in the share price looks like it's roughly in line with prevailing valuations. But those levels could well carry some risk, particularly since they are being goosed by furious merger-and-acquisition activity in the pharmaceutical sector. In valuing Vertex in the current environment, investors may well be drawing some of their inspiration from AbbVie's (NYSE:ABBV) pursuit of Shire (NASDAQ:SHPG), for example, as Shire has a strong franchise in rare diseases.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier, and more accurately, than anyone else. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. To outsmart Wall Street and realize multibagger returns, see The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. Click here now.

Alex Dumortier, CFA, has no position in any stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers